One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC

One year after the approval of Inlexzo, a continuous gemcitabine intravesical device for BCG-unresponsive non–muscle-invasive bladder cancer, treatment options have expanded, reducing cystectomy rates and shifting patient management toward bladder preservation. The device offers a new administration method requiring different patient counselling and follow-up, with logistical advantages including room-temperature storage suitable for various clinical settings.

This Wire brief sits within Fusion42's coverage of Medtech.